L C H W Lutgens
Overview
Explore the profile of L C H W Lutgens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
578
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van den Heerik A, Aiyer K, Stelloo E, Jurgenliemk-Schulz I, Lutgens L, Jobsen J, et al.
Gynecol Oncol
. 2022 Jul;
166(3):530-537.
PMID: 35840357
Objective: Microcystic, elongated fragmented (MELF) pattern of myometrial invasion is a distinct histologic feature occasionally seen in low-grade endometrial carcinomas (EC). The prognostic relevance of MELF invasion was uncertain due...
2.
Wortman B, Astreinidou E, Laman M, van der Steen-Banasik E, Lutgens L, Westerveld H, et al.
Radiother Oncol
. 2020 Nov;
155:160-166.
PMID: 33159971
Objective: The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment for endometrial cancer. The quality assurance programme included a dummy run for vaginal brachytherapy prior to site activation, and...
3.
Wortman B, Creutzberg C, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L, et al.
Br J Cancer
. 2018 Oct;
119(9):1067-1074.
PMID: 30356126
Background: PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam radiotherapy (EBRT) with vaginal brachytherapy (VBT). We evaluated long-term outcomes combined with...
4.
Wortman B, Bosse T, Nout R, Lutgens L, van der Steen-Banasik E, Westerveld H, et al.
Gynecol Oncol
. 2018 Aug;
151(1):69-75.
PMID: 30078506
Objective: The Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-4a trial is a randomized trial for women with high-intermediate risk endometrial cancer (EC), comparing individualized adjuvant treatment based on a molecular-integrated...
5.
Mongula J, Slangen B, Lambregts D, Cellini F, Bakers F, Lutgens L, et al.
Radiat Oncol
. 2015 Dec;
10:252.
PMID: 26642877
Background: Cervical cancer is associated with a high yearly mortality. The presence of persistent disease after radiotherapy is a significant predictor of patient survival. The aim of our study was...
6.
Kunneman M, Pieterse A, Stiggelbout A, Nout R, Kamps M, Lutgens L, et al.
Br J Cancer
. 2014 Jun;
111(4):674-9.
PMID: 24921911
Background: Vaginal brachytherapy (VBT) in high-intermediate-risk endometrial cancer (EC) provides a significant reduction in the risk of local cancer recurrence, but without survival benefit and with increased mucosal atrophy. Five-year...
7.
Nout R, Smit V, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L, et al.
Lancet
. 2010 Mar;
375(9717):816-23.
PMID: 20206777
Background: After surgery for intermediate-risk endometrial carcinoma, the vagina is the most frequent site of recurrence. This study established whether vaginal brachytherapy (VBT) is as effective as pelvic external beam...
8.
Vanclee A, Lutgens L, Oving E, Deutz N, Gijbels M, Schouten H, et al.
Bone Marrow Transplant
. 2005 Sep;
36(10):907-15.
PMID: 16151417
Allogeneic stem cell transplantations (SCT) are currently being used as a therapy for hematological malignancies, some solid tumors and nonmalignant bone marrow deficiencies. Nevertheless, clinical applicability is limited due to...
9.
Blijlevens N, Lutgens L, Schattenberg A, Donnelly J
Bone Marrow Transplant
. 2004 Jun;
34(3):193-6.
PMID: 15170165
We noted a significant decline in the serum concentrations of citrulline of 32 haematopoietic stem cell transplant recipients following intensive myeloablative therapy during the first 3 weeks after transplantation when...
10.
de Rijke J, van der Putten H, Lutgens L, Voogd A, Kruitwagen R, Van Dijck J, et al.
Eur J Cancer
. 2002 Oct;
38(15):2041-7.
PMID: 12376210
Age at diagnosis has been proven to be an important determinant of the choice of initial treatment for several sites of cancer. Elderly patients are more likely to receive no...